

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 9/16, 9/50</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/10993</b> <b>(43) International Publication Date:</b> 18 April 1996 (18.04.96)
<b>(21) International Application Number:</b> PCT/US95/12964 <b>(22) International Filing Date:</b> 4 October 1995 (04.10.95) <b>(30) Priority Data:</b> 08/317,695      5 October 1994 (05.10.94)      US <b>(71) Applicant:</b> BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA [US/US]; Regent's Hall, 3835 Holdrege Street, Lincoln, NE 68503 (US). <b>(72) Inventors:</b> MAUGER, John, W.; 1126 Medical Plaza, Salt Lake City, UT 94112 (US). ROBINSON, Dennis, H.; 862 South 91st Street, Omaha, NE 68124 (US). <b>(74) Agent:</b> NEBEL, Heidi, Sease; Zarley, McKee, Thorne, Voorhees & Sease, Suite 3200, 801 Grand Avenue, Des Moines, IA 50309-2721 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> COATING FOR TASTE MASKING ORALLY ADMINISTERED BITTER DRUGS		
<b>(57) Abstract</b>  A pharmaceutical coating for taste masking oral medications is described which includes a unique combination of triglycerides and a polymer. The triglyceride mixture melts at body temperature and the copolymer causes the coating to dissolve upon reaching the acidic environment of the stomach.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**TITLE OF INVENTION: COATING FOR TASTE MASKING ORALLY  
ADMINISTERED BITTER DRUGS**

**BACKGROUND OF THE INVENTION**

The present invention relates to an improved coating for taste masking orally-administered bitter drugs and method for making the same.

The bitter after taste of many drugs which are orally administered, such as tablets, capsules or suspensions, often contributes to patient non-compliance in taking medicine. For many, the disagreeable taste of tablets or capsules causes difficulties in swallowing or causes patients to avoid taking their medication completely. The result is patients not receiving the optimal therapeutic value of their medication.

In addition, since elderly and pediatric patients often experience difficulty in swallowing tablets or capsules, these bitter drugs are often administered as a powder suspended in a flavored liquid via a pharmaceutical suspension. Since the drug is in a ground-up form in a suspension, the objectionable taste is increased since there is greater surface area of the drug presented for taste. In many cases, the objectionable taste cannot be circumvented by use of flavors and sweetening agents added to the pharmaceutical suspension.

Current state of the art taste masking technology uses microencapsulation techniques which rely primarily on polymer coating materials. These polymers are known to be permeable to aqueous solvents. Upon exposure to an aqueous environment, drug leaching is a frequent occurrence with these coatings since they are greatly porous and therefore permeable to water. In addition, their effectiveness for taste-masking purposes is acknowledged as being less than perfect.

Therefore, a primary object of the present invention is the provision of an improved coating for taste masking orally administered drugs and a method for making the same.

A further object of the present invention is the provision of an improved pharmaceutical coating which is non-permeable for taste masking purposes.

A further object of the present invention is the provision of an improved coating for taste masking orally administered drugs which will maintain its integrity during the brief transit period in the mouth but release the medication in the gastric fluid of the stomach.

A further object of the present invention is the provision of an improved coating for taste masking orally administered drugs that will dissolve at body temperature.

A still further object of the present invention is the provision of an improved coating for taste masking orally administered drugs and a method for making the same which is easily applied, economical in manufacture, and efficient in use.

#### SUMMARY OF THE INVENTION

The present invention involves the use of triglycerides in combination with a polymer as a coating for masking the taste of orally administered drugs. The triglyceride which can be a mixture is one which melts at body temperature. The polymer is one which causes the coating to dissolve at a pH of 5.5. Upon oral administration, the coating will remain intact during the brief transit in the mouth but then release the medication upon reaching the gastric fluid of the stomach.

In preparation, the triglycerides and polymer are dissolved together in an organic solvent. A drug to be coated is then suspended in this solution. After evaporating the organic solvent, remaining organic solvent is then removed from the coated drug using a separation technique. These steps may all be accomplished using conventional lab equipment.

The triglyceride/polymer combination prevents the drug coating from dissolving while still in the patient's mouth. The coated drug remains intact until reaching the stomach

where it is immediately released upon contacting the gastric fluid.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The minimum ingredients necessary for the present invention are triglycerides which, when mixed together, melt at body temperature and a polymer, that is insoluble at pH 7.4 and soluble in the stomach (i.e. which dissolves at a pH of 5.5 or lower). Emulsifying and suspending agents are compatible as well.

In practice, the patient places the medication in his/her mouth and for that brief moment, the triglyceride portion of the coating begins to melt since it is now at body temperature. The coating remains intact, however, since the polymer portion will only dissolve once it reaches a pH of 5.5, which is much more acidic than the pH of the mouth. The medication then travels down the esophagus and enters the stomach. Once in the acidic environment of the stomach, dissolution occurs and the medication is then available for absorption by the body.

Eudragit E™ is the tradename for an FDA approved cationic copolymer based on dimethylaminoethyl methacrylates and neutral methacrylic acid esters. It dissolves in gastric juice. Any non-toxic polymer that is insoluble at pH 7.4 and soluble in the stomach would be an acceptable alternative. Such polymers are those that are subject to acid catalyzed decomposition, e.g., hydrolysis, yet are stable at neutral pH.

Fattibase™ is the tradename for an FDA approved composition of triglycerides derived from palm, palm kernel, and coconut oils. It also contains glyceryl monostearate and polyoxyl stearate as emulsifying and suspending agents, respectfully, but neither is necessary for the coating to function properly. It is the triglycerides which cause the composition to melt at body temperature.

Alternative triglycerides which may be used in the present invention are any non-toxic acids derived from

vegetable oils such as coconut and palm kernel oil that have been modified by esterification or hydrogenation. These may be mixtures of monoglycerides, diglycerides, and triglycerides of saturated acids derived from these oils. Typically, these can be derivatives of fatty acids of carbon chain length C6 to C18; in particular derivatives of lauric, myristic, and palmitic acids. These are solid to semi-solid materials at room temperature. The characteristic melting points of these triglycerides is in the range of 37-40°C. Some examples include Cotomar® by Proctor & Gamble which consists of partially hydrogenated cottonseed oil; Wecobee FS® consisting of coconut and palm kernel oils; Witepsol E7S®; and Massa Estariorm A® by Edelleit-Werke Werner Schluter of Hamburg, Germany which consists of a mixture of triglycerides, diglycerides, and monoglycerides of saturated fatty acids.

Eudragit E™ and Fattibase™ are the preferred compounds for use in the present invention since they are both already FDA approved for oral use in the production of pharmaceutical preparations. In addition, they both possess the required chemical properties, i.e. melting and dissolution points, for successful use of the invention. However, other polymers or triglyceride combinations may also be used so long as they possess the same requisite chemical properties.

The amount of triglyceride/polymer used to coat a particular drug is related to the amount and surface area of the drug being coated. The formulator will determine the amount of coating material needed to give a coat of specified thickness. The formulation from the example used 33% by weight of coating material. This ratio could be varied considerably depending on the particular size and porosity of the core material and amount to be coated. It would also depend upon the relative bitterness of the drug.

In general, triglycerides are preferred over mono or diglycerides for being more generally compatible with drugs. Triglycerides contain no free carboxyl groups and, thus,

these groups are not free to chemically react with functional groups present on drugs.

Acetone is an organic solvent used for dissolving the Eudragit E™ and Fattibase™ in the example. The choice of organic solvent is related to its volatility, safety, and ability to dissolve both the triglycerides and polymer. Alcohols, such as methanol, ethanol and isopropyl, are therefore suitable as well as acetone. In addition, a co-solvent mixture, such as 50% by volume isopropyl alcohol and acetone, would be another workable possibility. The limitation for solvent use is based on toxicity considerations since some residual solvent may remain in the end product. Ethanol and acetone are the preferred solvents.

While metronidazole is used in the example, this process, in principle, could be applied to any solid drug which has a disagreeable or bitter taste when it dissolves in the mouth. Examples of classes of drugs which are problematic include but are not limited to antibiotics, analgesics, antihistamines, decongestants, antitussives, and steroids.

The coating materials may be easily applied using a variety of different methods, including spray coating and pan coating. These methods are well known in the art. As stated, the coating may be applied to any orally administered drug. For suspensions, the coating material will maintain its integrity to mask disagreeable taste in a liquid medium with a pH greater than 5.5 and stored at refrigerated temperatures.

Below is an example of a preferred combination of materials and methods for use in the present invention:

#### EXAMPLE

<u>MATERIAL</u>	<u>AMOUNT</u>
Eudragit E™	100mg
Fattibase™	200mg
Acetone	20ml
M tronidazole	1gm

**METHOD**

1. Dissolve 100mg Eudragit E™ and 200mg Fattibase™ and 20ml acetone in an evaporating dish using low heat and stirring.
2. Suspend 1gm metronidazole in acetone solution and place in hood. Evaporate acetone under conditions of vigorous stirring and at room temperature
3. Place coated material in a separatory funnel. Add 100ml cold water and shake well. Rinse through the funnel with cold water and collect coated material on a filter paper. Repeat this process at least three times to remove acetone and any uncoated drug.

In the specification there has been set forth a preferred embodiment of the invention, and all those specific terms are employed, these are used in a generic and descriptive sense only and not for purposes of limitation. Changes in the form and the proportion of parts as well as in the substitution of the equivalent or contemplated as circumstances may suggest or render expedient without departing from the spirit and scope of the invention as further defined in the following claims.



What is claimed is:

1. A coating for masking the disagreeable taste of drug particles comprising: a triglyceride mixture which melts at body temperature; and a polymer which dissolves at pH levels at or below 5.5.
2. A coating according to claim 1 wherein said triglyceride mixture consists of derivatives of palm, palm kernel, and coconut oil.
3. The triglyceride mixture of claims 1 consisting of derivatives of fatty acids, having carbon chain length C6 to C8.
4. The polymer of claim 1 wherein said polymer is a copolymer.
5. The copolymer of claim 4 wherein said copolymer is based on dimethylaminoethyl methacrylate and neutral methacrylic acid esters.
6. The polymer of claim 1 wherein said polymer is soluble in gastric juice.
7. A coating useful for masking the disagreeable taste of drug particles wherein said coating comprises a mixture of triglycerides and a polymer.
8. A method for preparing and coating drug particles for masking the disagreeable taste comprising: dissolving triglycerides and a polymer together in an organic solvent to form a mixture; suspending a drug in said mixture to form a coated drug; vaporating said organic solvent from said coated drug; and removing remaining said organic solvent from said drug.

9. The method of claim 8 wherein said triglycerides are derived from palm, palm kernel, and coconut oil.
10. The method of claim 8 wherein the polymer is a copolymer.
11. The method of claim 10 wherein the copolymer is based on dimethylaminoethyl methacrylate and neutral methacrylic acid esters.
12. The method of claim 8 wherein said organic solvent is an alcohol.
13. The method of claim 8 wherein the alcohol is ethanol.
14. The method of claim 8 wherein said organic solvent is acetone.
15. The method of claim 8 wherein said organic solvent is a mixture of an alcohol and acetone.
16. The method of claim 8 wherein said drug is metronidazole.
17. The method of claim 8 wherein said evaporation is done at room temperature using vigorous stirring.
18. The method of claim 8 wherein said removing is a process comprising: placing said coated drug in a separatory funnel; adding 100ml cold water; shaking the cold water/coated drug; rinsing said cold water/coated drug through a funnel using additional cold water; and collecting said coated drug on filter paper.
19. The removing process of claim 18 wherein the removing process is repeated at least three times.

20. A coated drug consisting essentially of: a disagreeable tasting drug; a triglyceride mixture which melts at body temperature; and a polymer which dissolves at pH levels at or below 5.5.

21. The disagreeable tasting drug of claim 20 wherein said disagreeable tasting drug is metronidazole.

22. The triglyceride mixture of claim 20 wherein said triglyceride mixture consists of derivatives of fatty acids of carbon chain C6 to C18.

23. The triglyceride mixture of claim 22 wherein the derivatives of fatty acids are lauric, myristic and palmitic acids.

24. The polymer of claim 20 wherein said polymer is a copolymer.

25. The copolymer of claim 24 wherein said copolymer is based in dimethylaminoethyl methacrylate and neutral methacrylic acid esters.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 95/12964

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K9/16 A61K9/50

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	WO,A,93 17667 (TAISHO PHARMACEUTICAL COL) 16 September 1993 see claims 1,5 see page 2, line 25 - page 3, line 6 see page 4, line 11 - page 5, line 6 see page 8, line 11 - line 14 ---	1,4-7, 20,22-25 2
P,X P,Y	WO,A,95 11665 (LABORATOIRES VIRBAC) 4 May 1995 see claims 1,10 -----	7 2

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*a\* document member of the same patent family

Date of the actual completion of the international search

24 January 1996

Date of mailing of the international search report

8.02.1996

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Ventura Amat, A

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 95/12964

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9317667	16-09-93	CA-A-	2131547	16-09-93
		EP-A-	0630233	28-12-94
		FI-A-	944165	09-09-94
		JP-A-	6116138	26-04-94
		NO-A-	943341	09-09-94
-----				
WO-A-9511665	04-05-95	FR-A-	2711525	05-05-95
		AU-B-	8109294	22-05-95
-----				

**THIS PAGE BLANK (USPTO)**